MZ
Therapeutic Areas
Turn Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| GX-03 | Eczema (Atopic Dermatitis) | Phase 1 |
| Unnamed Onychomycosis Program | Onychomycosis | Late-stage clinical |
| Hexagen™ Wound Dressing | Wound Care | Approved/FDA-cleared |
| Thermostable Vaccine Delivery | Infectious Disease (Global Health) | Not specified |
Leadership Team at Turn Therapeutics
BB
Bradley Burnam
Chief Executive Officer & Founder
DN
Dr. Neil Ghodadra, MD
Chief Medical Officer, Board Director
ZC
Zuraiz Chaudhary, CPA
Chief Accounting Officer, VP Finance
DR
Dr. Robert Redfield, M.D.
Former Director of CDC (External Collaborator/Interview Subject)